Bloom Science develops live biotherapeutic products that use engineered gut commensal microbes to replicate the multi‑pathway benefits of the ketogenic diet without dietary restriction. Their lead candidate, BL‑001, activates metabolic and neuroprotective pathways and has demonstrated safety, tolerability, and weight‑loss signals in early clinical trials for obesity and neurological disorders. The IrisRx™ platform combines synthetic biology and a proprietary microbial knowledgebase to accelerate the creation of therapies for metabolic and neurological diseases.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
2OLBFounders
Product
Problem
Patients with obesity and certain neurological disorders such as Dravet syndrome and ALS have limited therapeutic options that safely mimic the metabolic benefits of the ketogenic diet, which is difficult to maintain long‑term.
Solution
Bloom Science develops live biotherapeutic products that harness gut commensal microbes to reproduce the ketogenic diet’s multi‑pathway effects without requiring dietary restriction. Their lead candidate, BL‑001, is engineered to activate metabolic and neuroprotective pathways simultaneously, offering a safer, more tolerable alternative to existing pharmacologic approaches. Preclinical work demonstrated proof of mechanism, and early‑stage clinical trials have shown safety, tolerability, and weight‑loss signals in overweight participants. The company’s IrisRx™ discovery platform integrates synthetic biology and a proprietary knowledgebase to identify and optimize microbial strains for targeted metabolic and neurological indications.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as clinical researchers and healthcare providers focused on metabolic and neurological disease treatment.
Features
- Live biotherapeutic formulation (BL‑001) that delivers ketone‑like metabolic signaling via engineered gut microbes
- Multi‑pathway mechanism of action addressing both metabolic regulation and neuronal excitability
- Proven safety and tolerability in Phase 1b trials with statistically significant weight‑loss outcomes at 28 days
- IrisRx™ platform combining synthetic biology, high‑throughput screening, and a curated microbial knowledgebase to accelerate pipeline development
- Capability to develop therapeutics for a range of conditions, including obesity, Dravet syndrome, and amyotrophic lateral sclerosis